Contineum Therapeutics, Inc.

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for major depressive disorder. For more information, please visit www.contineum-tx.com.

Current securities

1. Other EventsSep 14, 2026
2. SCHEDULE 13G/A filingAug 14, 2026
3. 10-Q filingJul 30, 2026
4. Results of Operations and Financial ConditionJul 30, 2026
5. SCHEDULE 13G/A filingJul 17, 2026